Early Detection of Circulating Antigen and IgM-Associated Immune Complexes during Experimental Mycobacterium bovis Infection in Cattle.

Q2 Biochemistry, Genetics and Molecular Biology

Clinical and Vaccine Immunology Pub Date : 2017-06-05 Print Date: 2017-06-01 DOI:10.1128/CVI.00069-17

Konstantin P Lyashchenko, Rena Greenwald, Alina Sikar-Gang, Archana A Sridhara, Ashley Johnathan, Paul Lambotte, Javan Esfandiari, Mayara F Maggioli, Tyler C Thacker, Mitchell V Palmer, W Ray Waters

{"title":"Early Detection of Circulating Antigen and IgM-Associated Immune Complexes during Experimental Mycobacterium bovis Infection in Cattle.","authors":"Konstantin P Lyashchenko, Rena Greenwald, Alina Sikar-Gang, Archana A Sridhara, Ashley Johnathan, Paul Lambotte, Javan Esfandiari, Mayara F Maggioli, Tyler C Thacker, Mitchell V Palmer, W Ray Waters","doi":"10.1128/CVI.00069-17","DOIUrl":null,"url":null,"abstract":"The presence of circulating antigen in cattle experimentally infected with Mycobacterium bovis was demonstrated using dual-path platform (DPP) technology. The antigen capture immunoassays employed rabbit polyclonal antibody recognizing predominantly M. tuberculosis complex-specific epitopes and were able to detect soluble substances and whole cells of mycobacteria. The antigen found in serum appeared to be mostly bound to IgM, but not to IgG, within the immune complexes formed at early stages of M. bovis infection. The antigen was also detected in bile and urine, indicating possible clearance pathways. The data correlation analyses supported the idea of the role of IgM responses in antigen persistence during M. bovis infection. The antigen was detectable in serum months prior to detectable antibody seroconversion. This proof-of-concept study suggested the potential for improved immunodiagnostics for bovine tuberculosis.","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":"24 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1128/CVI.00069-17","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/CVI.00069-17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/6/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 15

Abstract

The presence of circulating antigen in cattle experimentally infected with Mycobacterium bovis was demonstrated using dual-path platform (DPP) technology. The antigen capture immunoassays employed rabbit polyclonal antibody recognizing predominantly M. tuberculosis complex-specific epitopes and were able to detect soluble substances and whole cells of mycobacteria. The antigen found in serum appeared to be mostly bound to IgM, but not to IgG, within the immune complexes formed at early stages of M. bovis infection. The antigen was also detected in bile and urine, indicating possible clearance pathways. The data correlation analyses supported the idea of the role of IgM responses in antigen persistence during M. bovis infection. The antigen was detectable in serum months prior to detectable antibody seroconversion. This proof-of-concept study suggested the potential for improved immunodiagnostics for bovine tuberculosis.

Abstract Image

查看原文本刊更多论文

牛分枝杆菌感染过程中循环抗原和igm相关免疫复合物的早期检测

利用双路平台(DPP)技术证实了牛分枝杆菌实验感染牛体内存在循环抗原。抗原捕获免疫测定采用兔多克隆抗体，主要识别结核分枝杆菌复合物特异性表位，能够检测分枝杆菌的可溶性物质和整个细胞。在牛分枝杆菌感染早期形成的免疫复合物内，血清中发现的抗原似乎主要与IgM结合，而不是与IgG结合。在胆汁和尿液中也检测到抗原，提示可能的清除途径。数据相关性分析支持IgM反应在牛分枝杆菌感染期间抗原持久性中的作用。该抗原在抗体血清转化检测前几个月在血清中检测到。这一概念验证研究提示了改进牛结核病免疫诊断的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Vaccine Immunology 医学-传染病学

CiteScore

2.88

自引率

0.00%

发文量

审稿时长

1.5 months

期刊介绍： Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.